Cost of sales expense for the third quarter 2025 was $0.02 million and primarily consists of royalty payments pursuant to Iterum’s license agreement with Pfizer Inc (Pfizer). Prior to approval in ...
Keyera Corp. (TSX: KEY) (“Keyera”) announced its third quarter financial results today, the highlights of which are included in this news release. To view ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback